Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far

Author(s): Manisha Saini, Minakshi Rana, Karun Bhatti, Rina Das*, Dinesh Kumar Mehta and Ram Mohan Chidurala

Volume 14, Issue 1, 2022

Published on: 06 August, 2021

Page: [11 - 19] Pages: 9

DOI: 10.2174/2589977513666210806122901

Price: $65

Abstract

The novel SARS-CoV-2 is a new disease that has caused severe destruction to human lives across the globe, including infection, mortality and financial crises, for which, scientific researchers have been directed towards the development of treatment and controlling measures against coronavirus. Currently, there has been no approved drug for the treatment of the disease, but several antiviral drugs have shown therapeutic effects from which, remdesivir and favipiravir are two such drugs. These drugs have shown some therapeutic potential in the treatment of COVID-19 by inhibiting viral enzyme RNA-dependent RNA polymerase. The purpose of this systematic review is to provide an overview of the effectiveness of these two drugs based on the clinical trials reported in current published data.

Keywords: Coronavirus, COVID-19, SARS-CoV-2, antiviral, remdesivir, favipiravir.

« Previous Next »
Graphical Abstract

[1]
Ali MJ, Hanif M, Haider MA, et al. Treatment options for COVID-19: a review. Front Med (Lausanne) 2020; 7: 480.
[http://dx.doi.org/10.3389/fmed.2020.00480] [PMID: 32850922]
[2]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[3]
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Med 2021; 91(1): 157-60.
[http://dx.doi.org/10.23750%2Fabm.v91i1.9397] [PMID: 32191675]
[4]
World Health Organization Coronavirus disease. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[5]
Daga M. From SARS-CoV to coronavirus disease 2019 (COVID-19) - a brief review. J Adv Res Med 2020; 06(04): 1-9.
[http://dx.doi.org/10.24321/2349.7181.201917]
[6]
Mackenzie JS, Smith DW. COVID-19-A novel zoonotic disease: a review of the disease, the virus, and public health measures. Asia Pac J Public Health 2020; 32(4): 145-53.
[http://dx.doi.org/10.1177/1010539520931326] [PMID: 32475144]
[7]
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433.
[http://dx.doi.org/10.1016/j.jaut.2020.102433] [PMID: 32113704]
[8]
World Health Organization Coronavirus disease (COVID-19) 2021. Available from: https://www.who.int/vietnam/news/detail/14-07-2020-q-a-how-is-covid-19-transmitted
[9]
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[10]
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7(1): 11.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 32169119]
[11]
Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J Infect Public Health 2020; 13(9): 1187-95.
[http://dx.doi.org/10.1016/j.jiph.2020.07.013] [PMID: 32773212]
[12]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 323(18): 1824-36.
[PMID: 32282022]
[13]
Wu R, Wang L, Kuo HD, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep 2020; 6(3): 1-15.
[http://dx.doi.org/10.1007/s40495-020-00216-7] [PMID: 32395418]
[14]
Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D. The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics 2021; 11(4): 1690-702.
[http://dx.doi.org/10.7150/thno.53691] [PMID: 33408775]
[15]
The COVID-19 vaccine race. Gaviorg 2021. Available from: https://www.gavi.org/vaccineswork/covid-19-vaccine-race
[16]
Anatomy of a molecule. What makes remdesivir unique 2021. Available from: https://www.asbmb.org/asbmb-today/science/031720/what-makes-remdesivir-a-promising-antiviral
[17]
Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020; 585(7824): 273-6.
[http://dx.doi.org/10.1038/s41586-020-2423-5] [PMID: 32516797]
[18]
Wang Y, Zhou F, Zhang D, et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials 2020; 21(1): 422.
[http://dx.doi.org/10.1186/s13063-020-04352-9] [PMID: 32448345]
[19]
Agrawal U, Raju R, Udwadia ZF. Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020; 76(4): 370-6.
[http://dx.doi.org/10.1016/j.mjafi.2020.08.004] [PMID: 32895599]
[20]
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017; 93(7): 449-63.
[http://dx.doi.org/10.2183/pjab.93.027] [PMID: 28769016]
[21]
Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: an update. Biomed Pharmacother 2020; 130: 110532.
[http://dx.doi.org/10.1016/j.biopha.2020.110532] [PMID: 32707440]
[22]
Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 2020; 40(7): 659-71.
[http://dx.doi.org/10.1002/phar.2429] [PMID: 32446287]
[23]
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 2020; 34(1): e00162-20.
[http://dx.doi.org/10.1128/CMR.00162-20] [PMID: 33055231]
[24]
National Center for Biotechnology Information. PubChem Compound Summary for CID 492405, Favipiravir 2021. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Favipiravir
[25]
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020; 209: 107512.
[http://dx.doi.org/10.1016/j.pharmthera.2020.107512] [PMID: 32097670]
[26]
Favipiravir: Uses, interactions, mechanism of action. DrugBank Online 2021. Available from: https://go.drugbank.com/drugs/DB12466
[27]
Mokobi F. Favipiravir- properties, uses, mechanism, side effects, COVID-19. Microbe notes 2021. Available from: https://microbenotes.com/favipiravir/
[28]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[29]
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[30]
Pasquini Z, Montalti R, Temperoni C, et al. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother 2020; 75(11): 3359-65.
[http://dx.doi.org/10.1093/jac/dkaa321] [PMID: 32829390]
[31]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[32]
Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res 2020; 158: 104899.
[http://dx.doi.org/10.1016/j.phrs.2020.104899] [PMID: 32407959]
[33]
McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. Am J Obstet Gynecol MFM 2020; 2(3): 100164.
[http://dx.doi.org/10.1016/j.ajogmf.2020.100164] [PMID: 32838267]
[34]
Burwick R, Yawetz S, Stephenson K, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019. Clin Infect Dis 2020.
[http://dx.doi.org/10.1093/cid/ciaa1466]
[35]
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate covid-19: a randomized clinical trial. JAMA 2020; 324(11): 1048-57.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]
[36]
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in patients with Severe Covid-19. N Engl J Med 2020; 383(19): 1827-37.
[http://dx.doi.org/10.1056/NEJMoa2015301] [PMID: 32459919]
[37]
Dubert M, Visseaux B, Isernia V, et al. Case report study of the first five covid-19 patients treated with remdesivir in france. Int J Infect Dis 2020; 98: 290-3.
[http://dx.doi.org/10.1016/j.ijid.2020.06.093] [PMID: 32619764]
[38]
Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19. A Randomized Clinical Trial 2020.
[39]
Koshi E, Saito S, Okazaki M, et al. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN Case Rep 2020; 10(1): 126-31.
[PMID: 32940880]
[40]
Dauby N, Van Praet S, Vanhomwegen C, Veliziotis I, Konopnicki D, Roman A. Tolerability of favipiravir therapy in critically ill patients with COVID-19: a report of four cases. J Med Virol 2021; 93(2): 689-91.
[http://dx.doi.org/10.1002/jmv.26488] [PMID: 32886358]
[41]
Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care 2020; 24(1): 413.
[http://dx.doi.org/10.1186/s13054-020-03137-5] [PMID: 32646499]
[42]
Murohashi K, Hagiwara E, Kitayama T, et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: a report of 11 cases. Respir Investig 2020; 58(6): 430-4.
[http://dx.doi.org/10.1016/j.resinv.2020.08.001] [PMID: 32893160]
[43]
Inoue H, Jinno M, Ohta S, et al. Combination treatment of short- course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respir Med Case Rep 2020; 31: 101200.
[http://dx.doi.org/10.1016/j.rmcr.2020.101200] [PMID: 32868989]
[44]
Takahashi H, Iwasaki Y, Watanabe T, et al. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis 2020; 100: 283-5.
[http://dx.doi.org/10.1016/j.ijid.2020.08.047] [PMID: 32829044]
[45]
Ivashchenko A, Dmitriev K, Vostokova N, Azarova V, Blinow A, Egorova A, et al. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 2020; ciaa1176..
[http://dx.doi.org/10.1093/cid/ciaa1176]
[46]
Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother 2021; 133: 110825.
[http://dx.doi.org/10.1016/j.biopha.2020.110825] [PMID: 33378989]

Rights & Permissions Print Cite
Article Metrics
37
1
© 2024 Bentham Science Publishers | Privacy Policy